Article Text

Download PDFPDF
  1. Amanda Beaini

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases

Application Receipt Date(s): April 16, 2013

This Funding Opportunity Announcement (FOA) represents the third phase of the NIAID Immune Mechanisms of Virus Control Program (IMVC). The first phase was awarded as exploratory R21 grants in fiscal year 2007 (RFA-AI-07-008) and the second phase as either U01 or U19 cooperative agreements in fiscal year 2009 (RFA-AI-08-013). All qualified investigators are invited to apply to this FOA; prior funding under the first or second phases or through NIAID or NIH is NOT required.

The lack of effective vaccines and drug treatments for many viruses presents a health concern of significant proportions. Host defenses against viruses involve both innate and adaptive immune mechanisms, but the basic processes and the interactions of these two arms of the immune response in anti-virus defense are not completely understood, especially in humans. This FOA will continue to support basic immunological research focused on the parameters underlying the immune response to either virus infection or vaccination. Studies involving multiple viruses are encouraged to foster discovery of generalizable principles of anti-viral immunity. The goal of this program is to discover and define novel basic immune mechanisms that provide a more sophisticated understanding of the immune response to virus infection, and provide potential new targets for future vaccine and therapeutic drug development. It is NOT the purpose of this program to apply currently accepted immunological concepts to the development of improved anti-virus vaccines or therapies. For example, conventional antibody measurements used to test new vaccine candidates would not be considered responsive in the absence of studies on immune mechanisms of antibody protection.

Specific Areas of Research Interest

The National Institute of Allergy and Infectious Diseases invites multi-project applications to be part of a network of synergistic research teams focused on the immunological parameters of …

View Full Text